Abstract 16P
Background
Ovarian cancer (OC) is the second gynecological malignancy among women and presents high rates of recurrence associated with chemoresistance. Tumor cells adjust their energy metabolism in favor of their rapid progression. Melatonin (Mel), a hormone produced and secreted by the pineal gland during darkness, has obvious anti-tumor activities. Therefore, we investigated the mechanistic role of Mel on energy metabolism in human OC cells (SKOV-3 and CAISMOV24 cells), with special focus on glycolytic metabolism in addition to cell signaling molecules.
Methods
Cell lines were treated with Mel at concentrations of 3.4 μM for SKOV-3 and 7 μM for CAISMOV24 based on the cell cytotoxicity (CC50) for 24 h; a luzindole-treated group was used to test the influence of melatonin receptors, MT1 and MT2. Protein levels of glycolytic enzymes were analyzed by western blot and kinase levels were measured by multiplex assay.
Results
Melatonin levels dropped by half in the OC cells. We observed a significant decline in the levels of HIF-1α, G6PDH, GAPDH, LDH, and PDH in OC cells treated with melatonin regardless of the presence of luzindole, thus proving its receptor-independent actions; conversely, the luzindole-exposed groups had an upregulation of these proteins. In regard to kinases signaling, SKOV-3 cells treated with melatonin had a reduction in the concentration of CREB, JNK, NF-kB, p-38, ERK1/2, Akt, p70s6k, STAT3, and STAT5, all of them associated with tumor growth, metastasis, and recruitment of oncostatic components. In the CAISMOV24 cells, these molecules were reduced after the combination of melatonin with luzindole.
Conclusions
These findings showed that melatonin potentially regulates energy-related processes in OC cells, thereby favoring the reversal of the Warburg effect, in addition to attenuating cell signaling involved with tumor progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute of Biosciences of Botucatu.
Funding
CAPES, FAPESP (grant number: 2021/12971-7), CNPq (304108/2020-0).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
40P - Development of radiolabelled plerixafor as a theranostic molecule for targeting CXCR4 receptor expressing cancers: A translational study
Presenter: Tamanna Lakhanpal
Session: Cocktail & Poster Display session
Resources:
Abstract
41P - BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
Presenter: Beatriz Alonso de Castro
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Prognostic impact of the tumor immune microenvironment in adrenocortical cancer
Presenter: Nano Pachuashvili
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy
Presenter: Lauren Wood
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Discovery of CBO-212, a first-in-class drug Fc-conjugate (DFC), targeting CD73 in cancer
Presenter: James Levin
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Efficacy analysis and mechanism exploration of furmonertinib for advanced NSCLC with EGFR exon 20 insertion mutation
Presenter: Xiao Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - Treatment management in RAS and BRAF mutations in patients with metastatic colorectal cancer
Presenter: Merve Özkan
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - KRAS mutation, the molecular landscape of lung adenocarcinoma in the Portuguese population
Presenter: Carolina Trabulo
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Toxicity profile in early clinical trials with fibroblast growth factor receptor (FGFR) inhibitors (FGFRi): 10-years experience of a drug development unit
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - Antitumor efficacy of polypyrrole-polyethyleneimine nanocomplex to target B-cell lymphoma
Presenter: Thi Thuy Nguyen
Session: Cocktail & Poster Display session
Resources:
Abstract